RBC Capital Maintains Outperform on ACADIA Pharmaceuticals, Raises Price Target to $36

Benzinga Newsdesk www.benzinga.com Positive 89.3%

Neg 0% Neu 0% Pos 89.3%

RBC Capital analyst Brian Abrahams maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Outperform and raises the price target from $29 to $36.